


THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method for the treatment, amelioration and/or prophylaxis of a neurological condition which comprises the administration of an effective amount of a compound of formula I:



I

15 in which

R is O or S;

R^1 is independently selected from H, optionally substituted alkyl, optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted aryl; optionally substituted heterocyclyl; an antioxidant; a targeting moiety; CN; halo; CF_3 ; SO_3H ; and OR^2 , SR^2 , SOR^2 , SO_2R^2 , NR^2R^3 , $(CH_2)_nNR^2R^3$, $HCNOR^2$, $HCNNR^2R^3$, $CONR^2R^3$, $CSNR^2R^3$, $NCOR^2$, $NCSR^2$, COR^2 , CO_2R^2 , CSR^2 or $SO_2NR^2R^3$ in which R^2 and R^3 are independently selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heterocyclyl, an antioxidant or a targeting moiety and n is an integer of 1 to 10;

X is independently selected from CH, CO, N and NH;

Z is independently selected from CH, CO, N, NH and O;

Y is absent or together with the ring to which it is attached forms a 5- or 6-membered optionally substituted aryl or a 5- or 6-membered optionally substituted heterocyclyl;

m is an integer from 1 to 3; and

p is an integer from 1 to 4,


salts, hydrates, solvates, derivatives, pro-drugs, tautomers and/or isomers thereof to a subject in need thereof,

35 with the provisos that:

(i) at least one of X and Z is other than CH;

- 163 -


(ii) phanquinone or tautomers thereof are excluded i.e., when R is O, R¹ at position 7 is OH, X is CH and Y is absent, then Z is not



5


(iii) when R is O, Y is absent, Z is CH, X is CH other than at position 3

where X is N, m is 2 and R¹ is



15

at position 3, then R¹ at position 2 is not







or  ; and

25











(iv) clioquinol i.e, when R is O, Y is absent, Z and X are CH and m is 2, Then R¹ at position 5 is not chloro and R¹ at position 7 is not iodo.


30 2. A method according to claim 1, in which the compound of formula I is selected from the following:






- 165 -


- 5
- 10
- 15
- 20
- 25
- 30
- 35
- pyrido[3,2-d]pyrimidin-4-ol;
- pyrido[2-3-d]pyridazin-8-ol;
- [1,7]naphthyridin-8-ol;
- [1,5]naphthyridine-4,8-diol;
- [1,5]naphthyridine-8-ol;
- pyrido[3,4-b]pyrazin-8-ol;
- pyrido[3,4-b]pyrazin-5-ol;
- pyridol[4,3-d]pyrimidin-8-ol;
- 4-hydroxy-4a,8a-dihydro-pyrano[3,2,b]pyridin-2-one;
- 8-hydroxy-6H-[1,6]naphthyridin-5-one;
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 



8-hydroxy-6H-[1,6]naphthyridin-5-one;




dibenzo[a,g]quinolizin-8-one; and



4-hydroxy-1H-pyrido[3,2-d]pyridin-2-one

in which R^1 , m , n and p are as defined in claim 1 and q is an integer of 1 or 2.

3. A method according to claim 1 or claim 2 in which the compound of formula I is a compound of formula IA



IA

in which

R , R^1 and m are as defined in claim 1;


W is CH , N or NH ;

U is CH , CO or N ; and

Y' is absent or together with the ring to which it is attached forms a 6 membered N -containing optionally substituted heterocycl.

4. A method according to claim 3 in which the compound of formula IA is selected from the following:


(i) Formula Ia



Ia

in which R , R^1 , m and q are as defined above;


(ii) Formula Ib



Ib

in which R , R^1 , m and q are as defined in any one of claims 1 to 3;


(iii) Formula Ic



Ic


in which R , R^1 , m and q are as defined in any one of claims 1 to 3;

(iv) Formula Id




in which R, R¹, m and q are as defined in any one of claims 1 to 3;

(v) Formula Ie



in which R, R¹, m and q are as defined in any one of claims 1 to 3; and

(vi) Formula If




in which R¹ and m are as defined in any one of claims 1 to 3.

5. A method according to any one of claims 1 to 4 in which R in the compound of formula I is O.

6. A method according to any one of claims 1 to 5 in which R¹ in the compound of formula I is halo, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted alkyl, OR², SR², (CH₂)_nNR²R³, CONR²R³ and NCOR² in which n, R² and R³ are as defined in any one of claims 1 to 3.




7. A method according to any one of claims 1 to 6 in which R¹ in the compound of formula I is fluoro, iodo, chloro, optionally substituted phenyl, an optionally substituted unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, an optionally substituted saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms, an optionally substituted saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, optionally substituted C₁₋₄ alkyl, optionally substituted C₂₋₆ cycloalkyl, optionally substituted C₁₋₆ alkoxy, optionally substituted thio, CH₂NR⁴R⁵ in which R⁴ and R⁵ are independently selected from H and C₁₋₄ alkyl or CONH(CH₂)₂R⁶ in which R⁶ is optionally substituted heterocyclyl.

8. A method according to any one of claims 1 to 7 in which Y in the compound of formula I is an optionally substituted phenyl, an optionally substituted unsaturated 5- or 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms or an optionally substituted saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms.
9. A method according to any one of claims 1 to 8, in which the compound of formula I is as follows:





- 170 -


5




10



15



1066




20


1064

1065

25




1053



1045


30



1070

35

- 171 -



10. A method according to any one of claims 1 to 9, in which the neurological
25 condition is a neurodegenerative disorder.
11. A method according to claim 10, in which the neurodegenerative disorder is
neurodegenerative amyloidosis.
- 30 12. A method according to claim 10 or claim 11, in which the neurodegenerative
disorder is sporadic or familial Alzheimer's disease, amyotrophic lateral sclerosis,
cataract, Parkinson's disease, Creutzfeldt-Jacob disease and its new variant associated
with "mad cow" disease, Huntington's disease, dementia with Lewy body formation,
multiple system atrophy, Hallerboden-Spatz disease, diffuse Lewy body disease, fatal
35 familial insomnia, Gertsman Straussler Sheinker disease, hereditary cerebral
haemorrhage with amyloidosis-Dutch type, multiple sclerosis, tauopathies, motor
neuron disease or prion diseases.

13. A method according to claim 12, in which the neurodegenerative disorder is Parkinson's disease.
- 5 14. A method according to any one of claims 10 to 12, in which the neurodegenerative disorder is an A β -related condition.
15. A method according to claim 14, in which the A β -related condition is Alzheimer's disease or dementia associated with Down syndrome or one of several
10 forms of autosomal dominant forms of familial Alzheimer's disease.
16. A method according to any one of the preceding claims which slows, reduces or arrests the cognitive decline of the subject.
- 15 17. A method according to any one of the preceding claims, which further comprises separate, sequential or simultaneous administration of another medicament.
18. A method according to claim 17, in which the other medicament is an inhibitor of the acetylcholinesterase active site, an antioxidant, an anti-inflammatory agent or an
20 oestrogenic agent.
19. A method according to any one of the preceding claims, in which the compound of formula I is administered orally, topically or parenterally.
- 25 20. Use of the compound of formula I as defined in any one of claims 1 to 9, in the manufacture of a medicament for the treatment, amelioration and/or prophylaxis of a neurological condition.
21. Use of a compound of formula I as defined in any one of claims 1 to 9 for the
30 treatment, amelioration and/or prophylaxis of a neurological condition.
22. A compound of formula I as defined in claims 1 to 9 for use in the treatment, amelioration and/or prophylaxis of a neurological condition.
- 35 23. Use of the compound of formula I as defined in any one of claims 1 to 9, as a pharmaceutical.

24. Use according to claim 23, in which the pharmaceutical is a neurotherapeutic or neuroprotective agent.

25. Use according to claim 23 or claim 24, in which the pharmaceutical is an
5 antiamyloidogenic agent.

26. A pharmaceutical or veterinary composition comprising the compound of formula I as defined above in any one of claims 1 to 9 and a pharmaceutically or
10 veterinarily acceptable carrier.

27. A composition according to claim 26 which further comprises another medicament.

28. A composition according to claim 27, in which the other medicament is an
15 inhibitor of the acetylcholinesterase active site, an antioxidant, an anti-inflammatory agent or an oestrogenic agent.

29. A compound of formula II which is a compound of formula I as defined in any one of claims 1 to 9, with the further proviso that at least one R¹ is other than H.

20


30. A compound of formula IA as defined in claim 3.

31. Compounds of the formulae Ia, Ib, Ic, Id, Ie and If as defined in claim 4.

25 32. A compound as defined in claim 9 excluding 1049, 1048, 1026 and 1045.

33. A process for the preparation of the compound of formula II defined in claim 29 as described herein.

30 34. A compound of the formula:



35